Introduction: Thymic carcinomas and thymic neuroendocrine tumors are rare diseases often treated with surgical resection. Currently, there are no guidelines regarding nodal dissection at the time of tumor resection. Moreover, the prognostic significance of nodal metastases is unclear. The goal of this study was to define the incidence and prognostic relevance of nodal metastases in patients with thymic carcinoma and thymic neuroendocrine tumors.

Methods: The Surveillance, Epidemiology and End Results database was queried for patients who underwent surgical resection of thymic carcinoma or a thymic neuroendocrine tumor with documented pathological examination of lymph nodes. The incidence of nodal metastases and the impact on survival were examined.

Results: We identified 176 patients with thymic carcinoma and 53 with thymic neuroendocrine tumors. A median of three lymph nodes was sampled per patient. Positive metastasis to at least one lymph node was identified in 92 patients (40.2%). Nodal metastasis was more common in patients with thymic neuroendocrine tumors than in patients with thymic carcinoma (62.3% versus 33.5%). In multivariate analysis, nodal metastasis was more likely in patients with thymic neuroendocrine tumors and with more advanced tumors. The presence of nodal metastases had significant, independent, adverse impact on survival (hazard ratio, 2.933, 95% confidence interval, 1.903-4.521, p = 0.001). Median survival was 47 months in patients with nodal metastasis and 124 months in patients without nodal metastases (p < 0.001).

Conclusions: Nodal status seems to be an important prognostic factor in patients with thymic carcinoma and thymic neuroendocrine tumors. Nodal sampling should be performed during resection of these thymic malignancies.

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000660DOI Listing

Publication Analysis

Top Keywords

thymic neuroendocrine
32
patients thymic
28
nodal metastases
24
thymic carcinoma
24
neuroendocrine tumors
24
carcinoma thymic
20
thymic
16
nodal
12
nodal metastasis
12
patients
11

Similar Publications

Thymic epithelial tumors (TETs) are rare neoplasms that include thymomas, thymic carcinomas (TCs), and thymic neuroendocrine neoplasms (TNENs). These three tumor categories differ in aggressiveness, the incidence of recurrence after resection, the pattern of recurrence, and survival outcomes. Owing to the tumor's rarity, randomized trials have not been performed in the initial treatment setting.

View Article and Find Full Text PDF

Ectopic ACTH syndrome caused by thymic neuroendocrine tumour - stages of treatment.

Endokrynol Pol

December 2024

Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland.

Not required for Clinical Vignette.

View Article and Find Full Text PDF

Thymic mimetic cells are molecular hybrids between medullary-thymic-epithelial cells (mTECs) and diverse peripheral cell types. They are involved in eliminating autoreactive T cells and can perform supplementary functions reflective of their peripheral-cell counterparts. Current knowledge about mimetic cells derives largely from mouse models.

View Article and Find Full Text PDF

Surgical treatment of thymic epithelial tumor and myasthenia gravis.

Front Surg

November 2024

Department of Thoracic Surgery, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Türkiye.

Article Synopsis
  • * Thymomas grow slowly and are localized, while thymic carcinomas grow quickly and can spread, with respective 5-year survival rates of 78% and 30%.
  • * Treatment depends on tumor resectability, starting with surgery for early-stage cases, followed by chemotherapy for more advanced stages, while conditions like myasthenia gravis are associated with these tumors and can be treated through various methods, including extended thymectomy.
View Article and Find Full Text PDF

Efficacy, safety, and prognostic factors of capecitabine plus temozolomide regimen in patients with atypical thymic carcinoids.

Ther Adv Med Oncol

November 2024

Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, No.58 Zhongshan Er Road, Guangdong Province, Guangzhou, China.

Background And Objectives: Atypical thymic carcinoids (ATCs) are rare mediastinal malignancies that lack established treatment guidelines. Capecitabine and temozolomide (CapTem) has demonstrated significant efficacy in pancreatic neuroendocrine neoplasms (NENs), while its applicability and effectiveness in ATCs remain underexplored. This study seeks to investigate the efficacy, safety, and prognostic factors associated with CapTem in ATC patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!